Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anemia
Pharma
Bristol Myers' clinical woes deepen with failed Reblozyl ph. 3
With the Reblozyl flop, all four of the pivotal trials that have read out this year for BMS’ currently marketed drugs have turned up negative.
Angus Liu
Jul 18, 2025 11:28am
Akebia sketches out pivotal Vafseo study in nondialysis patients
Mar 13, 2025 3:28pm
CSL Vifor promises marketing campaign to resolve EU probe
Jul 22, 2024 11:18am
After high-profile snub, Akebia plots vadadustat resubmission
Aug 24, 2023 10:40am
FibroGen CEO Enrique Conterno hits the exit after 3-year stint
Jul 25, 2023 2:02pm
ASCO: BMS' $4B plan for Reblozyl takes shape—with one caveat
May 25, 2023 5:00pm
